ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Fight Back! Win the War Being Waged Against Your Immune System

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

Study Shows How Ancient Chinese Herb May Act As Alzheimer Drug

  [ 6 votes ]   [ Discuss This Article ]
By Press Release by the Weizmann Institute • • January 1, 1997

REHOVOT, Israel -- January 1, 1997 -- A new Weizmann Institute study shows exactly how a substance derived from a moss long used in Chinese folk medicine blocks a brain enzyme that may be involved in Alzheimer disease. In the study, reported in the January issue of Nature Structural Biology, the scientists solved the 3-D structure of a complex made up of the natural substance Huperzine A (HupA) -- extracted from the Huperzia serrata moss used in China for centuries as a medicine called Qian Ceng Ta -- and the brain enzyme acetylcholinesterase (AChE). The determination of the structure revealed a strikingly good fit between HupA and the enzyme and may provide a possible starting point for designing a new generation of Alzheimer drugs with improved properties.

"It is as if this natural substance were ingeniously designed to fit into the exact spot in AChE where it will do the most good," says crystallographer Prof. Joel Sussman, one of the authors of the study.

The research was performed by graduate student Mia Raves together with crystallographer Dr. Michal Harel and Profs. Sussman and Israel Silman, all of the Weizmann Institute. It involved close collaboration with Prof. Alan Kozikowski, a medicinal chemist at Georgetown University in Washington, D.C., who was the first to synthesize HupA in a test tube, and Dr. Yuan-Ping Pang, a chemist at the Mayo Clinic in Jacksonville, Florida, who had made theoretical predictions of the HupA-AChE interaction.

According to one theory, memory loss and other cognitive deficits in Alzheimer patients result from degeneration of nerve cells that release the message- carrying chemical acetylcholine. The acetylcholine shortage that ensues is compounded by the action of AChE, the enzyme that breaks down acetylcholine in the body. Two Alzheimer drugs approved by the US Food and Drug Administration, tacrine (COGNEX) and E2020 (ARICEPT), work by inhibiting AChE. HupA, which differs from these drugs in chemical structure but also inhibits AChE, is currently under investigation in China and elsewhere as a possible Alzheimer's drug.

The new study -- performed by X-ray crystallography -- revealed exactly how the blocking of the enzyme by HupA takes place: HupA slides smoothly into the active site of AChE where acetylcholine is broken down, and latches onto this site via a very large number of subtle chemical links. This binding closes off the enzyme's "cutting" machinery and keeps acetylcholine out of danger.

According to neurochemist Prof. Silman, "such specific binding means that HupA could be a potent drug even when used in small quantities, so that the risk of side effects would be minimal." These risks are relatively small to begin with because HupA is believed to possess very low toxicity.

The scientists worked with high-quality crystals of AChE derived from electric organ tissue of the Torpedo, a fish that is one of the richest sources of this enzyme. Due to the very high degree of similarity in the amino-acid sequence of Torpedo and human AChE, it is likely that the Torpedo 3-D structure is a very good model of the human enzyme. The Torpedo AChE crystals were soaked with HupA, and then exposed to a narrow X-ray beam, producing a diffraction pattern from which a 3-D computer image of AChE-HupA binding could be obtained.

In the past few years, Harel, Silman and Sussman have conducted a number of studies that shed new light on medications used to treat Alzheimer disease. Several years ago, they determined the structure of AChE and showed that it has a very deep chasm -- known as the "aromatic gorge" -- inside of which axcetyline is broken down. They then solved the structure formed by AChE and tacrine, and found that tacrine works by binding to the active site of the enzyme in place of acetylcholine.

The study of HupA-AChE binding was supported by the US Army Medical, Research and Development Command, the Weizmann Institute's Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly, and the Scientific Cooperation of the European Union with Third Mediterranean Countries through the Israel Ministry of Science. Prof. Silman, a member of the Weizmann Institute's Neurobiology Department, holds the Bernstein-Mason Chair of Neurochemistry. Prof. Sussman and Dr. Harel are members of the Weizmann Institute's Structural Biology Department. Sussman also heads the Protein Data Bank of the Brookhaven National Laboratory in Upton, New York.

The Weizmann Institute of Science is a major center of scientific research and graduate study located in Rechovot, Israel. Its 2400 scientists, students and support staffs are engaged in more than 850 research projects across the spectrum of contemporary science.

Source: Weizmann Institute Press Release: January 1, 1997

Weizmann Institute Contacts:

Susan Shalev
Projects Coordinator
Public Affairs Dept.

Prof. Joel Sussman
(972) 8-934-2638

Prof. Israel Silman
(972) 8-934-3649

Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Mitochondria Ignite™ with NT Factor® Energy NADH™ 12.5mg

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map